British pharmaceutical giant GSK has held firm on its annual group forecasts despite experiencing a decline in vaccine sales, with strong performance in specialist medicines helping to offset the downturn.
British pharmaceutical giant GSK has held firm on its annual group forecasts despite experiencing a decline in vaccine sales, with strong performance in specialist medicines helping to offset the downturn.






